Safe Harbor Statement

Transcription

1

2 Safe Harbor Statement This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the plan for Alimera to file for the expanded indication for posterior uveitis in 17 EU countries within 8 months and that Alimera is expecting revenue from posterior uveitis in the first quarter of Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "contemplate," "predict," "project," "target," "likely," "potential," "continue," "ongoing," "will," "would," "should," "could," or the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, market acceptance and physician awareness of ILUVIEN in the U.S. and Europe, including for posterior uveitis, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at Additional factors may also be set forth in those sections of Alimera s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, to be filed with the SEC in the third quarter of In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in this presentation are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this presentation (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise Alimera Sciences, All Rights Reserved 2

3 ILUVIEN: Unique DME Treatment Continuous Microdosing Delivery for Continuous Therapy in Patients with DME Eliminates the inconsistent treatment of other intermittent options Continuous Drug Delivery of the lowest available corticosteroid Patient friendly Proven to last up to 36 months Long-acting efficacy with a single injection Up to 12 times longer than the next comparable long-acting product 2017 Alimera Sciences, All Rights Reserved 3

4 USER Study = U.S. Retrospective Chart Review in Patients Receiving ILUVIEN

5 USER Study Overview Center Patients Treated, n (%) Eyes Treated, n All Centers 130 (100%) 160 Cincinnati Eye 37 (28.5%) 49 Georgia Retina 15 (11.5%) 19 Retina Health Institute 53 (40.8%) 59 Southern Eye 25 (19.2%) 33 Patients must have received ILUVIEN prior to January 1, 2016 for the treatment of DME in at least one eye. Objectives Determine correlation in ocular outcomes to DME treatments prior and post ILUVIEN administration Compare number of DME treatments before and after ILUVIEN administration Compare IOP signals associated with ILUVIEN to IOP signals reported in FAME Alimera Sciences, All Rights Reserved 5

6 Change in Visual Acuity, Entire Population 2017 Alimera Sciences, All Rights Reserved 6

7 Change in Visual Acuity, Entire Population 2017 Alimera Sciences, All Rights Reserved 7

8 Change in Retinal Thickness, Entire Population 2017 Alimera Sciences, All Rights Reserved 8

9 Mean IOP Over Time, Entire Population 2017 Alimera Sciences, All Rights Reserved 9

10 Financial Overview As of 6/30/17, all amounts are unaudited $34.4M Global Revenue Q $10.4M Full Year 2016 $34.4M $22.4M $8.6M International Gross Margin Q % Full Year % $7.3M International Net Loss Q ($2.8M) Full Year 2016 ($33.2M) $15.2M U.S. FY2015 FY2016 $25.8M U.S. Cash & Cash Equivalents (as of 6/30/2017) $26.9M 2017 Alimera Sciences, All Rights Reserved 10

11 ILUVIEN for Posterior Uveitis Percentage of Patients with Uveitis Recurrence 53.8% Recently announced acquisition of rights for Posterior Uveitis rights for ILUVIEN in EMEA 21.8% Plan to file for expanded indication in 17 EU countries within 8 months Expecting revenue from Posterior Uveitis beginning in 1Q19 Sham ILUVIEN Results of second Phase 3 Study 2017 Alimera Sciences, All Rights Reserved 11

12